



GASTRIC CANCER (MAY 2016): MOLECULAR ONCOLOGY TUMOR BOARDS

COURSE REFERENCES

Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. *Adv Anat Pathol*. 2011 Jan;18(1):53-9. ([View Abstract](#))

Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw*. 2013 May 1;11(5):531-46. ([Full Text](#))

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet*. 2010 Aug 28;376(9742):687-97. ([Full Text](#))

Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. *Br J Cancer*. 2011 Apr 26;104(9):1372-6. ([Full Text](#))

Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*. 2014 Jan 4;383(9911):31-9. ([Full Text](#))

Fusco N, Rocco EG, Del Conte C, et al. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. *Mod Pathol*. 2013 Jun;26(6):816-24. ([Full Text](#))

Galdy S, Cella CA, Spada F, et al. Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials. *Crit Rev Oncol Hematol*. 2016 Mar;99:1-12. ([Full Text](#))

Grillo F, Fassan M, Ceccaroli C, et al. The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. *Transl Oncol*. 2013 Feb;6(1):10-6. ([Full Text](#))

Gullo I, Grillo F, Molinaro L, et al. Minimum biopsy set for HER2 evaluation in gastric and gastro-oesophageal junction cancer. *Endosc Int Open*. 2015 Apr;3(2). ([Full Text](#))

Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial. *J Clin Oncol*. 2016 Feb 10;34(5):443-51. ([Full Text](#))

Hokins S, Yang GY. FDG PET imaging in the staging and management of gastric cancer. *J Gastrointest Oncol*. 2011 Mar; 2(1): 39-44. ([Full Text](#))

Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. *Ann Oncol*. 2012 Oct;23(10):2656-62. ([Full Text](#))

Kang YK, Rha SY, Tassone P, et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. *Br J Cancer*. 2014 Aug 12;111(4):660-6. doi: 10.1038/bjc.2014.356. Epub 2014 Jun 24. ([Full Text](#))

Kurokawa Y, Sugimoto N, Miwa H, et al. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). *Br J Cancer*. 2014 Mar 4;110(5):1163-8. ([Full Text](#))

Markar SR, Mackenzie H, Mikhail S, et al. Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England. *Gastric Cancer*. 2016 Mar 3. [Epub ahead of print] ([View Abstract](#))

Okines AF, Thompson LC, Cunningham D, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. *Ann Oncol*. 2013 May;24(5):1253-61. ([Full Text](#))

Pirrelli M, Caruso ML, Di Maggio M, et al. Are biopsy specimens predictive of HER2 status in gastric cancer patients? *Dig Dis Sci*. 2013 Feb;58(2):397-404. ([View Abstract](#))

Qui WS, Yue L, Ding AP, et al. Co-expression of ER-beta and HER2 associated with poorer prognosis in primary breast cancer. *Clin Invest Med*. 2009 Jun 1;32(3):E250-60. ([View Abstract](#))

Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. *Mod Pathol*. 2012 May;25(5):637-50. ([Full Text](#))

Saito T, Kondo C, Shitara K, et al. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case. *Pathol Int*. 2015 Jun;65(6):309-17. ([View Abstract](#))

Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. *J Clin Oncol*. 2014 Jul 1;32(19):2039-49. ([Full Text](#))

Schoppmann SF, Jesch B, Zacherl J, et al. HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases. *Br J Surg*. 2011 Oct;98(10):1408-13. ([View Abstract](#))

Selcukbiricik F, Erdamar S, Buyukunal E, et al. Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy? *Asian Pac J Cancer Prev*. 2014;15(24):10607-11. ([View Abstract](#))

Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol*. 2013

May;14(6):461-71. ([Full Text](#))

Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. *Gastric Cancer*. 2015 Jul;18(3):476-84. ([Full Text](#))

Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol*. 2014 Oct;15(11):1224-35. ([Full Text](#))